Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) VP Donald Bobo, Jr. sold 48,900 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $103.05, for a total transaction of $5,039,145.00. Following the completion of the sale, the vice president directly owned 22,798 shares of the company’s stock, valued at $2,349,333.90. This represents a 68.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Up 2.5%
Shares of EW traded up $2.58 during mid-day trading on Monday, hitting $104.72. 6,295,752 shares of the company’s stock were exchanged, compared to its average volume of 4,543,305. The stock has a market cap of $60.21 billion, a price-to-earnings ratio of 59.16, a P/E/G ratio of 2.72 and a beta of 0.85. The firm has a fifty day moving average of $88.92 and a two-hundred day moving average of $85.78. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. Edwards Lifesciences Corporation has a twelve month low of $74.66 and a twelve month high of $105.37.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.06. The business had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. Edwards Lifesciences’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3.02 earnings per share for the current year.
Institutional Investors Weigh In On Edwards Lifesciences
Analyst Ratings Changes
A number of analysts have weighed in on EW shares. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $113.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday. Rothschild & Co Redburn increased their price objective on Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a report on Monday, July 27th. BTIG Research raised their price objective on Edwards Lifesciences from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 target price (up from $101.00) on shares of Edwards Lifesciences in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Thursday, October 15th. Twenty-three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $108.88.
View Our Latest Stock Analysis on Edwards Lifesciences
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.
The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
